Biologická léčba hepatocelulárního karcinomu

Číslo: 5 / 2010 (Obsah)
Rubrika: Farmakoterapeutické postupy
Obor: Onkologie
Autoři: MUDr. Jan Novotný, Ph.D., MUDr. Martin Oliverius1
Autoři - působiště: Onkologická klinika VFN a 1. LF UK, Praha
1 Klinika transplantační chirurgie IKEM, Praha
Klíčová slova: hepatocelulární karcinom, systémová léčba, biologická léčba, sorafenib
Citace: 1 Bosch FX, Ribes J, Díaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(Suppl 1): S5–16. 2 Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG. The liver and portal hypertension. Philadelphia: Saunders, 1964. 3 Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707–16. 4 Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90. 5 Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34. 6 Therasse P, Arbruck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–16. 7 Abou-Alfa GK, Johnson P, Knox J, et al. Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC). Presented at the 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. 2008:128 [Abstract]. 8 Zhu AX, Sahami DV, Duda DG, et al. Efficacy, safety and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009;27:3027–35. 9 Faivre S, Raymond E, Douillard J, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma. J Clin Oncol 2007;25(Suppl):18s.Abstract 3546. 10 Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843–50. 11 Decaens T, Luciani A, Itti E. Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma. Presented at the 2009 Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, CA. 2009:244[Abstract]. 12 Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657–63. 13 Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059–67. 14 Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007;110:581–9. 15 Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008;112:2733–9. 16 Raoul JL, Finn RS, Kang YK, et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). In: Proceedings of the 2009 ASCO annual meeting. J Clin Oncol 2009; 27:15s [Abstract 4577]. 17 Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009;64:777–83. 18 Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13:5549s–55s. 19 Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010;80:550–60.

Souhrn

Léčba hepatocelulárního karcinomu doznala v posledních letech velkých změn. Transplantace jater se stala běžnou součástí léčebných postupů u vybraných skupin nemocných. Systémová léčba pokročilého onemocnění, která až donedávna neznamenala žádný přínos pro naše pacienty, prodělala díky biologické léčbě kvalitativní skok, nabízející prodloužené přežívání nemocných. Vývoj v této oblasti byl otevřen publikováním příznivých výsledků léčby sorafenibem ve studii SHARP a nyní je následován velkou skupinou dalších molekul.

Literatura

1 Bosch FX, Ribes J, Díaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(Suppl 1): S5–16. 2 Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG. The liver and portal hypertension. Philadelphia: Saunders, 1964. 3 Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707–16. 4 Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90. 5 Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34. 6 Therasse P, Arbruck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–16. 7 Abou-Alfa GK, Johnson P, Knox J, et al. Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC). Presented at the 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. 2008:128 [Abstract]. 8 Zhu AX, Sahami DV, Duda DG, et al. Efficacy, safety and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J Clin Oncol 2009;27:3027–35. 9 Faivre S, Raymond E, Douillard J, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma. J Clin Oncol 2007;25(Suppl):18s.Abstract 3546. 10 Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843–50. 11 Decaens T, Luciani A, Itti E. Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma. Presented at the 2009 Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, CA. 2009:244[Abstract]. 12 Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657–63. 13 Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059–67. 14 Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007;110:581–9. 15 Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008;112:2733–9. 16 Raoul JL, Finn RS, Kang YK, et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). In: Proceedings of the 2009 ASCO annual meeting. J Clin Oncol 2009; 27:15s [Abstract 4577]. 17 Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009;64:777–83. 18 Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13:5549s–55s. 19 Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010;80:550–60.

Celý článek je dostupný jen pro předplatitele časopisu


Přihlášení

 

Předplatné

Více o předplatném

 
 
 
Jste odborný pracovník ve zdravotnictví?
Jsem odborníkem ve smyslu §2a Zákona č. 40/1995 Sb., o regulaci reklamy, ve znění pozdějších předpisů, čili jsem osobou oprávněnou předepisovat léčivé přípravky nebo osobou vydávat léčivé přípravky.

Potvrzuji, že jsem se seznámil/a s definicí odborník
dle zákona č. 40/1995 Sb.
Potvrzuji, že jsem se seznámil/a s riziky, jimž se jiná osoba než odborník vystavuje, vstoupí-li na stránky určené pro odborníky